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1  | INTRODUC TION
Liver transplantation saves lives in liver failure and hepatocellular 
carcinoma and, in the context of an ever‐increasing demand for 
transplantation, promoting equality of access has become a focus.1‒4 
Recent reports from the United States have described worsened 
outcomes for liver transplantation for those living at greater dis‐
tances or travel times from transplant centers; the effect is seen 
prior to listing, from listing, and from the point of transplantation.5,6 
Such worsened outcomes are also reported for the transplantation 
of other solid organs7 and for treatment of cancer for those living at 
greater distances from specialist cancer care centers.8 Conversely, 
improved outcomes are reported for centralization of services for 
certain specialist procedures (eg, surgery for pancreatic cancer 
in the United Kingdom, and for liver transplantation in the United 
States).9,10
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In the United States, distance from liver transplant center correlates with worsened 
outcomes; the effects of geography elsewhere are unassessed. We performed a na‐
tional	registry	analysis	of	United	Kingdom	listings	for	liver	transplantation	(1995‐2014)	
and assessed whether travel time to transplant center correlates with outcome. 
There	were	11	188	listings	assessed	(8490	transplanted),	with	a	median	travel	time	to	
center of 60 minutes (range 36‐86). Of the national population, 3.38 × 107 (55.1%) 
reside	≥60	minutes	from	a	center,	and	7.65	×	106 (12.5%) >119 minutes. After com‐
peting risk analysis, increasing travel time was associated with an increased risk of 
death after listing (subdistribution hazard ratios relative to <60 minutes of 1.33 for 
60‐119 and 1.27 for >119 minutes; P < 0.001) and reduced likelihood of transplanta‐
tion	or	recovery	(0.94	and	0.86;	P < 0.001). Among those transplanted, travel time 
was not associated with retransplant‐free survival (P = 0.532). We used our model to 
examine optimal placement of a new center and identify a single site with a total 
travel	 time	 reduction	 of	 ≈10%.	 Our	 findings	 of	 disparities	 in	 accessibility	 of	 liver	
transplantation showed worse outcomes following listing in those distant from their 
transplant center, and our description of a method to model a new center comple‐
ment existing data and support similar analyses of other networks.
K E Y W O R D S
business / management, clinical research / practice, disparities, health services and outcomes 
research, informatics, liver disease, liver transplantation / hepatology, organ transplantation 
in general, patient characteristics, patient referral
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The United Kingdom National Health Service (UK NHS) has a 
well‐established liver transplant program, and represents the only 
option for liver transplantation within the United Kingdom. Since 
1992, the NHS provision of care has been split between 7 cen‐
ters. Recent analyses of the provision of national liver transplant 
services have emphasized reducing disparity and considering the 
building of new transplant center(s) to do so.11‒14 In addition to po‐
tential effects on patient outcome, it is reported that proximity to 
treating transplant center is identified as a factor important to many 
liver transplant patients.15 To date, however, the roles of distance 
and travel time in UK liver transplantation have not been formally 
assessed.
In this analysis, we sought to describe the geographic distribution 
of UK patients using liver transplantation services, assess whether 
current variations in travel time are associated with differences in 
outcome, and to assess where a potential new liver transplant center 
might be best placed to minimize travel time.
2  | MATERIAL S AND METHODS
The NHS Blood and Transplant national registry was queried for all 
patients	≥18	years	old	listed	for	liver	transplantation	in	the	United	
Kingdom	from	1995	to	2014	inclusive;	approval	for	the	study	was	
given by the UK Transplant Registry. Patients listed for repeat 
transplants, those listed on a “super‐urgent” basis, those listed for 
simultaneous multi‐organ transplantation, and those listed from 
postal codes (postcodes) outside England, Scotland, or Wales were 
excluded (Figure 1). Those resident in Northern Ireland were ex‐
cluded because of the incomplete availability of Census data, in‐
complete availability of data on population liver‐related mortality, 
and the distorting effects of air travel. Data sources are summarized 
in Table S1.
To preserve anonymity, only the first portion of each patient’s 
postcode was available describing the “postcode district.” The longi‐
tude and latitude for the centroid of each of 2736 postcode districts 
(Figure S1) and the precise location of each renal or liver transplant 
center was then entered into the Google Maps API (Alphabet, Palo 
Alto, CA). The shortest driving distance and travel time, unadjusted 
for traffic conditions, were then calculated from each postcode 
district to each transplant center. Centers with a preexisting renal 
transplant center were chosen as a proxy for the presence of suffi‐
cient infrastructure to support a new liver transplant center. Travel 
times were divided into 3 groups: <60 minutes, 60‐119 minutes, and 
>119 minutes. Population estimates for postcode districts were ob‐
tained from the 2011 UK National Census; adjusted standardized 
mortality ratio (ASMR) estimates for liver disease were obtained 
for 2011 from national agencies. Geographic boundaries of the or‐
ganizational subunits for which ASMR was available were overlaid 
with postcode districts and each postcode district was assigned the 
ASMR for the healthcare administrative area with the most shared 
area. Mapping was performed using Quantum GIS v2.18.7 (https://
qgis.osgeo.org).
For the assessment of outcome from listing, death on the waiting 
list and de‐listing for worsening condition were treated as outcomes, 
with patients censored if they received a transplant or were de‐listed 
because of an improvement in their condition. For the assessment 
of outcome from transplantation, retransplant‐free survival was as‐
sessed. Here, the outcomes of interest were mortality and the receipt 
of a second transplant, with patients censored at the end of follow‐
up. Assessments were performed with both travel time and travel 
distance as both categorical and continuous variables. Primary liver 
diagnoses were categorized into the following categories: primary 
biliary cholangitis, autoimmune hepatitis, hepatitis B virus, primary 
F I G U R E  1   Flowchart of exclusions. Adult patients (17 186) were 
listed	for	liver	transplantation	from	1995	to	2014	inclusive.	After	
application of the exclusion criteria, an analysis cohort of 11 188 
was generated
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sclerosing cholangitis, alcohol, hepatitis C virus, nonalcoholic fatty 
liver disease, or other. The presence or absence of hepatocellular car‐
cinoma was coded separately from primary diagnosis. Those patients 
with missing data in 1 or more categories were excluded from the uni‐
variable analyses in question and entirely from multivariable analyses.
Univariable analyses were used to compare differences between 
the 3 travel time categories: the nptrend test in Stata for continuous 
variables,16 the Mann‐Whitney U test to compare travel time between 
2 categorical variables, and the Kruskal‐Wallis test to compare 3 or 
more categorical variables. To assess for outlying contributors of list‐
ings for liver transplantation, the relative contribution of different post‐
code areas—each including multiple postcode districts—to listings for 
liver transplantation, rates, and confidence intervals were calculated 
to generate a funnel plot according to the method of Spiegelhalter.17
To assess outcome from the point of listing for transplantation, 
competing‐risks regression models according to the method of Fine 
and Gray were constructed.18 Analyses were constructed both with 
death as the primary outcome and transplantation or recovery as a 
competing risk, and also with attaining transplantation or recovery 
as a primary outcome and death or all other outcomes as a compet‐
ing risk. To assess outcome following liver transplantation, a Cox 
proportional hazards model was constructed with the incidence of 
either death (of any cause) or retransplantation considered a failure.
In both competing risk and Cox models, variables other than 
travel time were selected for inclusion in the final model with a 
backwards stepwise approach with a cut‐off of P < .1. Visual inspec‐
tion was used to ensure no crossover of Kaplan‐Meier survival plots 
for each categorical value. For Fine‐Gray competing risk models, 
cumulative sums of residuals were used to confirm the appropri‐
ateness of the model constructed for each variable; for Cox models, 
Martingale and Cox‐Snell residuals were calculated.19 For skewed 
values with poor fit, logarithmic transforms were used (this was re‐
quired in 2 instances: intensive treatment unit stay duration and in‐
ternational normalized ratio). A value of P < .05 was assumed to be 
representative of statistical significance. Statistical analyses were 
conducted using StataMP v15.0 (StataCorp, College Station, TX) 
using the University of Birmingham’s BlueBEAR High Performance 
Computing Cluster.
3  | RESULTS
Adult listings (17 186) for liver transplantation were identified. 
After exclusions, 11 188 were included in subsequent analysis 
(Figure 1). Data on distance and travel time were available for 
11	184	 of	 11	188	 transplants	 (>99.9%),	 with	 the	 remainder	 not	
having a valid recorded postal code. The median distance to the 
nearest center was 67.3 km (interquartile range [IQR] 23.6‐107.6); 
median travel time was 60 minutes (IQR 36‐86).
F I G U R E  2   Geographic distribution of listings for liver 
transplantation. Geographic distribution of patients listed for 
liver	transplantation	in	England,	Scotland,	and	Wales	1995‐2014	
inclusive after the exclusions detailed in Figure 1
F I G U R E  3   Listings for liver transplantation by postcode area. 
The	number	of	listings	for	liver	transplantation	1995‐2014	for	each	
postcode area (n = 2736) was aggregated from the constituent 
postcode area and plotted against the 2011 National Census 
population. Confidence intervals at P = .05 and .002 were then 
generated to assess for those postcode areas contributing either 
more or fewer than expected listings. Those areas contributing 
fewer listings than expected at P < .002 are marked in blue; those 
contributing more at P < .002 are marked in red; text labels represent 
postcode areas. Postcode areas containing a liver transplant center 
(7) are plotted with a square rather than a circular marker
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Travel time to nearest transplant center was closely correlated 
with distance from nearest transplant center (r2 = 0.913; P < .001) 
(Figure S2). For the remainder of the analysis, travel time was used 
as the primary comparator. The majority of patients attended their 
nearest	 liver	 transplant	 center	 (8505	of	11	184;	76.0%)	 (Figure	2).	
Those who did not attend their nearest center were primarily resi‐
dent in areas of near equidistance between centers, or in the north‐
west or southwest of England (Figure S3).
Several postcode areas supplied a disproportionate number of 
total listings as a proportion of the resident population as at the 
2011 National Census population (Figure 3) at a confidence level 
of 3 standard deviations (P < .002). Among these were 6 out of 7 
postcode areas containing one of the liver transplant centers; the 
seventh transplant center—Birmingham—was located in a postcode 
area that contributed an excess of listings at P < .05 but not P < .002. 
Among postcode areas over the study period, there was a median of 
22.1 listings/100 000 population (IQR 18.8‐26.7).
3.1 | There is an uneven distribution of access to 
liver transplant centers across the United Kingdom
When calculated across the United Kingdom, marked variation 
in	 travel	 time	 to	 the	 nearest	 center	 was	 evident	 (Figure	 4A).	 Of	
those	 11	184	 listed	 for	 transplantation,	 5620	 (50.3%)	 were	 resi‐
dent	 ≥60	minutes	 from	 a	 liver	 transplant	 center,	 1262	 (11.3%)	
were	>119	minutes	away,	and	494	(4.4%)	were	≥180	minutes	away	
(Figure	4B).	With	respect	to	the	general	population	of	Great	Britain,	
as measured in the 2011 National Census (n = 6.13 × 107), approxi‐
mately 3.38 × 107	(55.1%)	people	were	resident	≥60	minutes	from	a	
liver transplant center, 7.65 × 106 (12.5%) were >119 minutes away, 
and	2.49	×	106 (4.0%)	were	≥180	minutes	away	(Figure	4C).
To assess whether there was a correlation between mortality 
from liver disease with travel time to nearest liver transplant center, 
we plotted ASMR for each postcode district against travel time. This 
revealed	a	negative	correlation	−3.51	ASMR	points	per	100	minutes	
F I G U R E  4   Travel time to nearest liver transplant center. A, Map of Great Britain showing the locations of current liver transplant 
centers (cyan circles), renal transplant centers without liver transplant capability (yellow circles), and calculated travel time to the nearest 
liver transplant center from each postcode district in 30‐minute intervals. B, Frequency distribution of travel time from postcode district of 
residence of patients listed for transplantation to the liver transplant center attended (n = 11 188). Red line denotes cumulative frequency. 
C, Frequency distribution of travel time from postcode district of residence of total resident population to the nearest liver transplant center 
(n = 6.13 × 107). Red line denotes cumulative frequency
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TA B L E  1   Study population characteristics
Variable Category
Listed patients Transplanted patients
n
Median (IQR) 
travel time 
(min) P n
Median (IQR) 
travel time 
(min) P
Age (years) ≤40	y 1733 64	(40‐100) .151 1296 63	(40‐100) .156
>40	≤	55	y 4725 64	(38‐97) 3593 63 (37‐97)
>55 y 4722 65 (39‐101) 3520 65 (38‐101)
Sex Male 7011 64	(38‐100) .289 5298 63 (37‐100) .333
Female 4168 65 (39‐98) 3110 65 (39‐99)
BMI (kg/m2) <25 4517 65 (39‐100) .795 3349 65 (39‐100) .838
≥25	<	30 3539 64	(37‐102) 2760 63 (37‐102)
≥30 2493 65	(40‐100) 1818 65	(40‐100)
Recipient 
ethnicity
White 9810 68	(41‐103) <.001 7417 67	(41‐103) <.001
Asian 961 45	(26‐65) 711 45	(26‐65)
Black 271 35 (19‐57) 194 34	(18‐55)
Other/mixed 132 35 (15‐59) 86 32 (12‐56)
Serum bilirubin 
(µmol/L)
≤30 2347 64	(37‐100) .012 1668 65 (37‐100) .043
>30	≤	60 2025 66	(41‐100) 1501 65	(40‐98)
>60 2834 66	(42‐100) 1993 65	(42‐101)
Serum sodium 
(mmol/L)
≤135 2741 67	(41‐100) .407 1885 66	(40‐100) .707
>135	≤	140 3285 64	(40‐98) 2400 64	(40‐98)
>140 1163 65	(40‐105) 864 65	(40‐105)
INR ≤1.2 2663 66	(40‐105) .112 1910 67	(40‐105) .077
>1.2	≤	1.6 2991 65	(40‐98) 2167 65	(40‐98)
>1.6 1512 64	(41‐95) 1056 64	(40‐95)
Serum 
creatinine 
(µmol/L)
≤60 1295 63 (39‐101) .138 945 63 (38‐100) .261
>60	≤	90 3418 65	(40‐100) 2589 65	(40‐100)
>90 2475 66	(41‐100) 1615 66	(40‐100)
Blood group O 5086 65 (39‐100) <.001 3567 64	(38‐100) .001
A 4321 66	(40‐102) 3520 65 (39‐100)
B 1325 55	(34‐90) 944 56	(34‐93)
AB 448 63 (36‐92) 378 65	(36‐94)
Diabetes 
mellitus
No 9937 64	(38‐99) .203 7531 64	(38‐100) .425
Yes 1243 65	(40‐101) 878 65 (39‐100)
Hemodialysis No 11056 64	(39‐100) .414 8350 64	(38‐100) .885
Yes 124 60 (37‐89) 59 63 (38‐98)
Liver disease PBC 1376 66	(42‐102) <.001 1162 66	(41‐102) <.001
AIH 494 70	(42‐102) 386 68	(42‐100)
HBV 436 47	(25‐84) 352 47	(24.5‐84)
PSC 1027 65	(41‐101) 854 66	(41‐102)
Other 1749 65	(40‐105) 1100 65	(38.5‐104)
Alcohol 2920 65 (38‐98) 2172 63 (38‐99)
HCV 1868 61	(35‐94) 1454 60 (35‐95)
NAFLD 428 66	(45‐99) 288 67	(46‐98)
HCC No 9797 65 (39‐99) .551 7324 64	(38‐99) .524
Yes 1383 63	(36‐104) 1085 63 (36‐100)
(Continues)
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of	 travel	 time	 (95%	confidence	 interval	 [CI]	 to	−2.97	 to	−4.04;	P < 
.001; r2	=	0.061;	Figures	S4	and	S5).
To simultaneously consider both population density and travel 
time to the nearest transplant center, we calculated the product of 
the resident population of each postcode district and the travel time 
to the nearest transplant center (Figure S6). The largest values of 
“person minutes” generated related to southwest England, south 
Wales, and around urban centers in northern England. We then re‐
peated this procedure but adjusted values according to the ASMR 
for that postcode district normalized to the average ASMR nation‐
wide (Figure S7). After this adjustment, the largest values of “person 
minutes” were evident in the northwest of England.
3.2 | Travel time is significantly correlated with 
worsened outcome from the point of listing for liver 
transplantation and a lower likelihood of receiving a 
liver transplant
To assess outcome after listing of transplant patients, we first divided 
patients into 3 groups: <60 minutes, 60‐119 minutes, and >119 minutes 
travel	time	to	the	center	used.	Of	the	11	184	patients	listed,	8865	were	
transplanted or removed because of an improvement in their condi‐
tion, 2228 had died or were removed because of deterioration in their 
condition, and 95 were still active on the transplant list. Median fol‐
low‐up from listing was 75 days (IQR 26‐179 days). Of those who died 
or were delisted for worsening, median time to event was 96 days (IQR 
34‐227	days).
The results of univariable analyses comparing average travel 
times across a range of factors are presented in Tables 1 and 2. 
Within the cohort of listed patients, travel times were found to 
differ significantly by ethnicity (P < .001), being longest in white 
patients; by blood group (P < .001), being shortest for group B 
potential recipients; and by liver disease, being shortest in viral 
hepatitis. Serum bilirubin was also found to increase significantly 
with travel time (P = .012), and travel time increased over the 
study period (P < .001), with a significant difference in travel time 
between transplant units (P < .001).
An unadjusted analysis of postlisting survival demonstrated sig‐
nificant differences between travel‐time categories (Figure 5A; P = 
.003	by	log‐rank	test),	with	a	hazard	ratio	of	1.21	(95%	CI:	1.03‐1.41,	
P = .020) for the >119 minutes vs <60 minutes groups. However, this 
did not account for the rates of transplantation or recovery, which 
were also found to differ significantly across the groups, being 
lowest in the >119 minutes group (HR: 0.91; 95% CI: 0.85‐0.96, 
P = .002, Figure 5B). As such, competing risks analyses were per‐
formed, to consider both of these outcomes simultaneously. These 
models also accounted for other confounding factors, in order to 
account for the baseline differences observed between the 3 travel 
time groups.
When considering death as the primary outcome (Table 3), the 
model found survival to be shorter in those with longer travel times 
(P < .001), with subdistribution hazard ratios (sHRs) of 1.33 (95% CI: 
1.12‐1.57, P = .001) for the 60‐119‐minute group, and 1.27 (1.01‐1.59, 
P = .037) for the >119‐minute group, relative to the <60‐minute group. 
When the competing risks model was reanalyzed with travel time as a 
continuous variable, there was a significant correlation with a greater 
risk of mortality with increasing travel time to transplanting center: 
sHR 1.09 (per 60 minutes, 95% CI: 1.02‐1.17, P = .013).
Variable Category
Listed patients Transplanted patients
n
Median (IQR) 
travel time 
(min) P n
Median (IQR) 
travel time 
(min) P
Transplant unit King’s College 2148 63 (37‐108) <.001 1585 62 (36‐108) <.001
Leeds 1866 61 (39‐78) 1312 58 (39‐78)
Birmingham 2723 93	(47‐123) 2095 93	(49‐123)
Edinburgh 1196 67 (50‐96) 920 66	(49‐94)
Cambridge 1359 75 (52‐96) 1074 75 (52‐95)
Royal Free 1188 44	(31‐62) 894 44	(31‐61)
Newcastle 700 32	(20‐54) 529 32 (20‐55)
Listing year 1995‐1999 2053 59 (33‐99) <.001 1708 60	(34‐99) .003
2000‐2004 2396 65 (39‐98) 1963 65 (39‐99)
2005‐2009 2833 65	(40‐97) 2000 64	(39‐97)
2010‐2014 3898 65	(40‐101) 2738 65	(40‐101)
AIH, autoimmune hepatitis; BMI, body mass index; INR, international normalized ratio; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, 
hepatitis C virus; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing 
cholangitis.
Values represent the median travel time for that category. The Mann‐Whitney test was used to compare travel times between 2 categorical variables; 
the Kruskal‐Wallis test was used to compare 3 or more categorical values; the nptrend test was used to test for trend across numerical values between 
tertiles. Blood results are from the point of listing. Bold P values are significant at P < .05.
TA B L E  1   (Continued)
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A similar competing risks model to the one described above was 
constructed but with attaining transplantation or recovering to the 
point of no longer needing a transplant as the outcome of interest, 
with death or delisting for a decline in condition as a competing 
risk. Here there was a reduced likelihood of receiving a transplant 
associated	 with	 longer	 travel	 time,	 with	 sHRs	 of	 0.94	 (0.88‐0.99,	
P = .039) for the 60‐119‐minute group and 0.86 (95% CI: 0.79‐0.93, 
P < .001) for the >119‐minute group, relative to the <60‐minute group 
(Table S2). When the model was reanalyzed with travel time as a con‐
tinuous variable, there was a significant correlation with a reduced 
likelihood of receiving a liver transplant and increasing travel time to 
transplanting center: sHR 0.95 (0.93‐0.98; per 60‐minute travel time), 
P = .001.
3.3 | Travel time is not significantly correlated with 
outcome following liver transplantation
We next looked for differences in outcome after transplan‐
tation associated with travel time by assessing regraft‐free 
survival	between	groups	of	travel	time.	Of	8490	patients	trans‐
planted, 3050 required retransplantation or died within median 
follow‐up of 1596 days (IQR 536‐3306 days). The results of 
Variable Category n
Median (IQR) travel 
time (min) P
Donor BMI (kg/m2) <25 3843 63 (37‐96) .004
≥25	<	30 2411 64	(38‐103)
≥30 1183 66	(40‐102)
Donor age (y) ≤40 2978 63 (38‐98) .122
>40	≤	55 2941 63 (38‐97)
>55 2490 65 (39‐102)
Cold ischemic time 
(min)
≤500 2792 65	(40‐101) .004
>500	≤	750 4137 64	(38‐98)
>750 1480 61	(34‐97)
Days in ITU (d) 1 2402 62 (38‐89) <.001
2 or 3 3543 65 (38‐103)
>3 2175 65 (38‐109)
Transplant weekday Sunday 1046 65 (37‐107) .726
Monday 1123 62 (36‐100)
Tuesday 1315 65 (38‐101)
Wednesday 1377 63 (39‐96)
Thursday 1233 64	(38‐100)
Friday 1199 63 (39‐95)
Saturday 1116 65	(41‐98)
CMV status D−R− 1447 68	(43‐105) <.001
D−R+ 2263 59 (35‐93)
D+	R+ 2280 61 (35‐100)
D+	R− 1399 69	(44‐103)
Donor sex Male 4488 66 (39‐102) <.001
Female 3921 62 (37‐95)
Donor ethnicity White 6914 65 (39‐100) .022
Asian 138 50 (31‐85)
Black 85 60 (37‐90)
Other/mixed 70 59	(35‐84)
Graft type DBD 7467 64	(38‐100) .645
DCD 941 65 (39‐100)
BMI, body mass index; CMV, cytomegalovirus; D, donor; DBD, donation after brain death; DCD, do‐
nation after cardiac death; ITU, intensive treatment unit; IQR, interquartile range; R, recipient.
Values either represent the median of the characteristic concerned or the median travel time for that 
category. The Mann‐Whitney test was used to compare travel times between 2 categorical variables; 
the Kruskal‐Wallis test was used to compare 3 or more categorical values; the nptrend test was used 
to test for trend across numerical values between tertiles. Bold P values are significant at P < .05.
TA B L E  2   Additional transplant‐related 
patient characteristics
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univariable analyses between travel time categories are presented in 
Tables 1 and 2, and the results were consistent with those for 
the cohort of listed patients, as previously described. An unad‐
justed analysis of survival demonstrated no significant differ‐
ences between travel‐time categories (P = .645	by	log‐rank	test)	
(Figure S8). A multivariable Cox proportional hazards model also 
found no significant difference in HR according to travel time cat‐
egory, after accounting for other potentially confounding factors 
(P = .532,	Table	4),	with	a	HR	of	0.99	(95%	CI:	0.82‐1.19,	P = .886) 
for the >119‐minute group vs <60‐minute group. Consistent re‐
sults were returned from sensitivity analyses where assessments 
for distance from transplant center or with travel time as a con‐
tinuous variable were considered (data not shown).
3.4 | The optimum site for an additional UK 
transplant center to reduce patient travel time 
is Bristol
Having demonstrated a correlation between increasing travel 
time and worsened outcome, we modeled the effect on total 
travel time to the nearest liver transplant center of an additional 
liver center. An additional center was modeled at each of the 
existing UK mainland renal transplant centers without current 
liver transplant facilities: Bristol, Cardiff, Coventry, Glasgow, 
Leicester, Liverpool, St George’s Hospital (London), the West 
London Renal and Transplant Centre (“Hammersmith,” London), 
The Royal London Hospital, Manchester, Nottingham, Oxford, 
Plymouth, Portsmouth, and Sheffield (15 centers; Figure S9A). 
We calculated the reduction in person minutes of travel time 
that	the	introduction	of	a	new	center	would	produce	in	each	of	4	
scenarios:	for	all	liver	transplant	patients	listed	1995‐2014	after	
the exclusions described above (Figure 6A), for all listed patients 
without exclusions applied (Figure 6B), for the total population 
(Figure 6C), and for the total population with adjustment for 
ASMR (Figure 6D). In each case, the greatest overall reduction 
in patient travel time was achieved by modeling the addition of a 
new center in Bristol. For liver transplant listings after exclusions, 
a predicted saving of 82 913 minutes (10.1%) was predicted with 
a center in Bristol, with other centers ranging from 72 603 min‐
utes (8.8%) with Cardiff to 10 063 minutes with Leicester (1.2%); 
analyses using different inclusion criteria returned consistent 
results. A map showing the effects of a new center at Bristol is 
shown as Figure S9B.
4  | DISCUSSION
Here we show that there is a significant disparity in travel time to 
liver transplant services across the United Kingdom. For those listed 
for transplantation, greater travel time to transplant center corre‐
lates with a worse outcome: a greater likelihood of death while listed 
and a lower likelihood of receiving a transplant. However, in contrast 
to reports from the United States, there was no apparent difference 
in outcome after transplantation for those living further from liver 
transplant centers.
We show that approximately 7.5 million people (around 12.5% 
of the population) live >2 hours travel from a liver transplant center 
in the United Kingdom. There are variations in disease pathogenesis 
with geography, with fewer people distant from a transplant center 
being listed for both hepatitis B‐ and C‐related disease, perhaps re‐
flecting the urban concentration of hepatitis and associations with 
ethnic grouping and relative wealth. Patients are also traveling fur‐
ther with time. A number of other factors including both recipient 
and donor ethnicity, donor sex blood groups, cytomegalovirus sta‐
tus, serum bilirubin, time spent in intensive treatment unit, and cold 
ischemic	 time	varied	significantly	by	distance.	The	 first	4	of	 these	
might reasonably be explained by variations in the populations using 
the individual transplant centers, while the causes of variations in 
the last 3 are less apparent. A trend to higher bilirubin in those trav‐
eling further may be consistent with delays in referral for transplan‐
tation,20 but this study lacks details of the denominator population 
that would be required to fully explore this. Interestingly, cold isch‐
emic time was lower for those living further away from transplant 
centers. One possible explanation for this finding is patients living 
F I G U R E  5   Outcome following listing for liver transplantation. 
A, Proportion of patients who had died following listing for liver 
transplantation categorized by travel time to listing transplant 
center (n = 11 188; P = .003 by log‐rank test). B, Proportion of 
patients who received transplantation or were removed from the 
waiting list because of an improvement in their clinical condition 
following listing for liver transplantation categorized by travel time 
to listing transplant center (n = 11 188; P = .005. by log‐rank test)
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Variable sHR (95% CI) P
Travel time tertiles — <.001
<60 min 1.00 —
60‐119 min 1.33 (1.12‐1.57) .001
>119 min 1.27 (1.01‐1.59) .037
Age (/10 y) 1.24	(1.15‐1.34) <.001
Serum bilirubin (/100 µmol/L) 1.23 (1.17‐1.30) <.001
Serum sodium (/10 mmol/L) 0.55	(0.48‐0.64) <.001
Serum creatinine (/100 µmol/L) 1.25 (1.15‐1.36) <.001
INR (per 2‐fold increase) 2.09	(1.60‐2.74) <.001
Transplant center — .002
King’s College 1.00 —
Leeds 0.95	(0.74‐1.23) .705
Birmingham 0.89 (0.71‐1.12) .328
Edinburgh 0.90 (0.69‐1.17) .432
Cambridge 0.57	(0.42‐0.77) <.001
Royal Free 0.91 (0.69‐1.22) .532
Newcastle 0.56	(0.37‐0.84) .006
HCC — —
No 1.00 ‐
Yes 0.35	(0.25‐0.48) <.001
Blood group — <.001
O 1.00 —
A 0.63 (0.53‐0.75) <.001
B 1.20	(0.96‐1.49) .102
AB 0.56 (0.36‐0.89) .015
Primary liver disease — <.001
PBC 1.00 —
AIH 0.95	(0.62‐1.45) .803
HBV 0.84	(0.48‐1.47) .543
PSC 0.62	(0.43‐0.90) .012
Other 1.69 (1.27‐2.25) <.001
Alcohol 0.94	(0.71‐1.23) .642
HCV 1.03	(0.76‐1.41) .835
NAFLD 1.22	(0.85‐1.74) .275
Ethnic group — .150
White 1.00 —
Asian 0.71 (0.51‐0.98) .038
Black 0.99 (0.59‐1.66) .965
Other/mixed 1.33	(0.64‐2.77) .447
AIH, autoimmune hepatitis; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; 
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; NAFLD, 
nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
Variables presented represent those from Table 1 retained in the competing risks model after 
backwards stepwise selection: covariables excluded because of the absence of a significant effect 
on outcome were: sex, BMI, INR, diabetes mellitus, hemodialysis, and listing year. Subdistribution 
hazard ratios (sHR) are presented along with upper and lower 95% CI. Only listings with complete 
data	are	included	(n	=	6744).	The	sHR	calculated	for	INR	and	days	in	intensive	treatment	unit	re‐
lates to an increase of 1 in the log2‐transformed variable (eg, a 2‐fold increase in INR). For the other 
continuous factors, sHRs are for increases of the stated number of units. Blood results are from the 
point of listing. Bold P values are significant at P < .05.
TA B L E  3   Risk of death from the 
point of listing for liver transplantation
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TA B L E  4   Cox model results for retransplant‐free survival following liver transplantation
Variable Hazard ratio (95% CI) P
Travel time tertile .532
<60 min 1.00 —
60‐119 min 0.91 (0.79‐1.05) .207
>119 min 0.99 (0.82‐1.19) .886
Primary liver disease <.001
PBC 1.00 —
AIH 1.34	(0.93‐1.94) .120
HBV 1.02 (0.68‐1.55) .910
PSC 1.96 (1.51‐2.55) <.001
Other 1.39 (1.07‐1.81) .014
Alcohol 1.29 (1.01‐1.65) .040
HCV 1.75	(1.37‐2.24) <.001
NAFLD 1.66 (1.16‐2.36) .006
CMV status .015
Donor−	Recipient− 1.00 —
Donor−	Recipient+ 0.99 (0.83‐1.19) .936
Donor+	Recipient+ 1.21	(1.01‐1.45) .040
Donor+	Recipient− 0.98 (0.80‐1.20) .842
Serum creatinine (/100 µmol/L) 1.20	(1.03‐1.40) .021
INR (per 2‐fold increase) 0.58	(0.42‐0.81) .001
Donor age (/10 y) 1.08 (1.03‐1.13) <.001
Transplant center .001
King's College 1.00 —
Leeds 1.56 (1.15‐2.10) .004
Birmingham 1.46	(1.13‐1.89) .004
Edinburgh 1.64	(1.23‐2.19) .001
Cambridge 1.73 (1.31‐2.30) <.001
Royal Free 1.40	(1.05‐1.87) .021
Newcastle 1.52 (1.08‐2.12) .015
Cold ischemic time (/100 min) 1.06 (1.01‐1.10) .011
Days in ITU (per doubling in d) 1.35	(1.28‐1.44) <.001
Listing year (/10 y) 0.68	(0.54‐0.86) .001
Recipient ethnicity .052
White 1.00 —
Asian 0.91 (0.72‐1.16) .458
Black 1.38	(0.94‐2.02) .100
Other/mixed 0.19 (0.05‐0.77) .020
Transplant type
DBD 1.00 —
DCD 1.66 (1.38‐1.99) <.001
AIH, autoimmune hepatitis; BMI, body mass index; CI, confidence interval; CMV, cytomegalovirus; DBD, donation after brain death; DCD, donation 
after cardiac death; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile 
range; ITU, intensive treatment unit; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
Variables presented represent those from Tables 1 and 2 retained in the competing risks model after backwards stepwise selection: covariables ex‐
cluded because of the absence of a significant effect on outcome were: Age, sex, BMI, serum bilirubin, serum sodium, INR, diabetes mellitus, hemodi‐
alysis, HCC, donor age, cold ischemic time, days in ITU, transplant weekday, CMV status, donor sex, and donor ethnicity. Hazard ratios (HR) are 
presented	along	with	upper	and	lower	95%	confidence	intervals.	Only	listings	with	complete	data	are	included	(n	=	4158).	The	HR	calculated	for	INR	
and days in ITU relates to an increase of 1 in the log2‐transformed variable, eg, a 2‐fold increase in INR. For the other continuous factors, HRs are for 
increases of the stated number of units. Blood results are from the point of listing. Bold P values are significant at P < .05.
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nearby being called in rapidly as second‐choice candidate after a 
problem with the first choice.
Our findings of a significant correlation between travel time 
to transplant center and worsened outcome after listing are 
consistent with the findings of 2 large US studies,5,6 but not all 
analyses of the US system.20,21 This study is not designed to ex‐
plain why such variations in outcome may occur, but potential 
explanations include less frequent pretransplant follow‐up or 
less specialized pretransplant care, delays in referral for trans‐
plantation not reflected in the covariables that we have, or an 
unmeasured preference for offering organs to those geograph‐
ically closer. Such differences warrant further examination and 
provide impetus to efforts to reduce such disparities in access 
to liver transplantation. In addition, we cannot account for pos‐
sible regional variations in the approach to listing or delisting 
patients. Indeed, differences in the general behavior of clinicians 
and/or patients further from transplant centers may also explain 
some of the variation in outcome we describe. Such variation 
might be amenable to educational approaches. However, major 
differences in behavior might also be expected to have effects 
on posttransplant outcomes, and these were not evident in this 
study.
In contrast to work from the United States, we do not, however, 
show variations in outcome after transplantation in those living further 
from their transplanting center. One possible reason is that the geog‐
raphy of the United Kingdom means that the most distant patients are 
F I G U R E  6   Modeled reductions in travel time by introduction of a new liver transplant center at various locations. The models described 
elsewhere in this document were repeated with the addition of a hypothetical new liver transplant center at each of 15 locations. The 
reduction in the number of minutes of traveling time for each listing for transplantation, or member of the population, to attend their nearest 
liver transplant center with and without the modeled new center was calculated. Panel A represents all listings for liver transplantation 
1995‐2014	after	the	application	of	our	exclusion	criteria;	Panel	B	represents	all	listings	without	exclusions;	Panel	C	represents	travel	for	the	
population of England, Scotland, and Wales as at the 2011 National Census; Panel D represents the same Census population but normalized 
to age‐adjusted standardized mortality rates (ASMR)
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still nearer a transplant center than their counterparts in the United 
States. However, in the analysis by Goldberg et al, differences in out‐
come were apparent when comparing 0‐100 and 100‐200 miles of dis‐
tance. Such distances are within those seen in the United Kingdom. In 
addition, the correlation of rurality or socioeconomic status and travel 
time from liver transplant center may differ between the United States 
and the United Kingdom and are not addressed in our study.
A further consideration is the different organization of the UK and 
US healthcare systems: The NHS represents a single system with a semi‐
formalized referral network,22 whereas multiple providers and funders 
contribute to the United Network for Organ Sharing network. Similar 
analyses of the effect of travel time and distance are not available for 
other liver transplant systems—either centralized or more diffuse.
Having demonstrated a correlation between greater travel time 
to transplant center and worsened outcome, we continued to model 
where a new liver transplant center might optimally be placed. We 
also note that patient preference, the logistics of organ procurement, 
and potential benefits to referral networks and pre/posttransplant 
care are also potential reasons for wishing to minimize distance be‐
tween patients and transplant center, but are not examined here. Our 
finding of the optimal site for a new liver transplant center differs 
from that expected by a simple inspection of distribution of the fre‐
quency of severe liver disease as measured by ASMR: In the United 
Kingdom, mortality rates from liver disease are greatest in the north‐
west	of	England.	The	 finding	 that	≈25%	of	patients	 listed	 for	 liver	
transplantation are seen in a center that is not their geographically 
closest suggests that factors other than travel time are also import‐
ant: possibilities include physician referral patterns,22 change of res‐
idence after initial referral, and differences in specialties between 
centers including for rarer causes.
Although our data set is relatively large with excess of 11 000 
listings considered, one potential concern is that with the multiple 
variables examined, an otherwise statistically significant outcome 
signal from travel time posttransplantation might be lost. This is 
made less likely by significant differences in HRs for posttransplant 
outcome in risk factors in other studies (eg, increased mortality in 
those receiving organs from deceased after cardiac death donors, 
those receiving grafts from older donors or with longer cold isch‐
emic times, and those with renal failure at listing).23,24
Weaknesses of this analysis include the moderate impreci‐
sion introduced by only using the first part of the postal code, 
although this was necessary to preserve relative anonymity, and 
these factors represent potential confounders of our findings. 
This imprecision also precludes estimates of social status and in‐
come based on place of residence, although we note that popu‐
lation rates of mortality from liver disease tend to be lower with 
greater travel time. Importantly, we only considered those who 
reached the point of listing for transplantation and are therefore 
unable to account for geographic variations in ability to access 
assessment for possible liver transplantation. We have, how‐
ever, attempted to account for this in our geographic analysis by 
using ASMR as a proxy for total liver disease. It is notable, how‐
ever, that a large proportion of liver‐related death in the United 
Kingdom is alcohol related and that these patients are often not 
referred for consideration of transplantation.12 In addition, we 
only considered mortality and a requirement for retransplanta‐
tion as outcomes; it is possible that patient experience, loss of 
productive work, financial cost, and other variables are affected 
by distance from transplant center. We were also unable to as‐
certain which patients changed their address; patient migration 
for the purposes of transplantation is reportedly common in the 
United States.25 We recorded variation in outcome between cen‐
ters in the United Kingdom both from the point of listing and from 
the point of transplantation. However, for the reasons explored 
above and because of the lack of information about the denomi‐
nator population including those who are not accepted for listing, 
further work would be necessary to understand this variation. 
Finally, in our modeling we do not consider the addition of more 
than one center to the current network.
The issue of how best to approach the provision of liver trans‐
plantation in the United Kingdom is challenging. We highlight dispar‐
ity in access to liver transplant centers and demonstrate a correlation 
between greater distance from transplant center and outcome from 
the point of listing for transplantation, although we do not prove 
causation. Further careful analysis will be required to guide future 
decisions on both the number and geographical distribution of liver 
transplant centers, including the consideration of factors other than 
simple mortality and chance of attaining transplantation.
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